# Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Source: https://onco.cc/trials/nct04434040/  
OnCo record `nct04434040` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of atezolizumab and sacituzumab govitecan in triple-negative breast cancer, run by Dana-Farber Cancer Institute, now recruiting.

## Summary

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) is a phase 2, interventional study registered as NCT04434040 by Dana-Farber Cancer Institute, with a registry enrolment figure of 40 participants, started 2020-07-02 and due to reach its primary completion in 2026-12-30. Interventions recorded: Atezolizumab; Sacituzumab govitecan. Conditions listed: Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNA. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04434040
- Phase: 2
- Setting: A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)
- Sponsor: Dana-Farber Cancer Institute
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT04434040: https://clinicaltrials.gov/study/NCT04434040

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04434040.json